J6E-MC-KWAN: A Phase 2, Multicenter, Randomized, Double-Blind, Active-Controlled Study of LY4268989 (MORF-057) Co-Administered with Mirikizumab in Adults with Moderately to Severely Active Ulcerative Colitis
Hungary, Spain, Denmark, Netherlands, Poland, Romania, Germany, Italy, Austria
Condition studied
Ulcerative Colitis
Investigational medicinal product(s)
MirikizumabPlacebo to MirikizumabPlacebo to match LYMirikizumab
Eligibility
Age group
65+ years, 18-64 years
Sex
Female, Male
Primary endpoint
The proportion of participants who achieve clinical remission with mMS at Week 12
Official registry record
This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.